Clinical trials: Multiple Sclerosis Relapse
Autoimmune Diseases, Relapsing Multiple Sclerosis
Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients
The proposed randomized, open label, with treat as usual control group (standard treatment or any disease modifying drugs), crossover phase II study will be conducted in 40 patients (n=20 per group) with the relapsing forms of…
- Trial name
- NCT03183869
- Testing
- Fecal microbiota
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Multiple Sclerosis, Relapsing-Remitting
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04448977
- Testing
- Ocrevus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis
Predictors of Progression Independent of Relapse Activity in Relapsing Remitting Multiple Sclerosis
The goal of this prospective observational cohort study is to determine the frequency of progression independent of relapse activity (PIRA) and identify its clinical, radiological, neuroaxonal, and functional predictors in…
- Trial name
- RRMS (NCT07762040)
- Where
- Egypt
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Assiut University
Multiple Sclerosis, Relapse
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
Ocrelizumab is a humanized anti-CD20 monoclonal antibody that showed in phase III trials a powerful effect on relapse rate and lesion load accumulation in the relapsing form of multiple sclerosis (RMS).
- Conditions
- Multiple Sclerosis, Relapse, Primary Progressive Multiple Sclerosis
- Trial name
- INN-MS (NCT03691077)
- Testing
- Ocrelizumab
- Where
- France
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Relapsing-Remitting Multiple Sclerosis
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
Since many years cognitive disorders are a main topic of clinical research in Multiple Sclerosis (MS) as there could be observed early on in the disease and could induce with time in patients significant socio-professional…
- Trial name
- SEPREV (NCT01805336)
- Testing
- Assessment of attentional functions by traditional tests, Assessment of attentional functions by virtual reality tests, Assessment of executive functions by traditional tests
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Multiple Sclerosis, Relapsing-Remitting, Healthy Controls
The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis
Personal identity is composed of multiple facets of the self that are constructed and nourished through memories of past experiences (i.e., autobiographical memory) and the imagination of events that may occur in the future…
- Trial name
- SELFSEP (NCT05648292)
- Testing
- Neuropsychological tests and psychological questionnaires
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Centre d'Investigation Clinique et Technologique 805
Multiple Sclerosis
A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months
To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population…
- Trial name
- GASWI (NCT01695434)
- Testing
- MRI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Multiple Sclerosis, Covid19
MS Relapses During COVID-19 Pandemic
Throughout the COVID-19 pandemic, and to our knowledge there have been no studies looking systematically at the occurrence of MS relapses and their subsequent management, during the peak of the first wave of the pandemic.
- Conditions
- Multiple Sclerosis, Covid19, Relapsing Remitting Multiple Sclerosis
- Trial name
- NCT04858763
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Multiple Sclerosis
Avonex 15 Year Long Term Follow-up Study
The Avonex Fifteen-year Long-term Follow-up of Patients with Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs (ASSURANCE), was a single-time-point evaluation of patients…
- Trial name
- 15yASSURANCE (NCT00525343)
- Where
- 4 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Biogen